Scholarlink

<p>Pulmonary fibrosis (PF) is a fatal disease with limited therapeutic options. Myofibroblasts, central to the pathogenesis of PF, are the primary collagen-producing cells that drive fibrosis. However, therapeutic targeting of myofibroblasts faces formidable challenges owing to their autonomous activation, persistent proliferation, and resistance to apoptosis. Here, we show that lithium carbonate (LC), a clinically approved mood stabilizer, effectively depletes myofibroblasts during fibrosis progression. Mechanistically, LC promotes alveolar macrophages (AMs) to produce TNF-α, which activates pro-caspase-8 signaling without inducing myofibroblast apoptosis. LC directly binds to and inactivates pro-caspase-8, inducing to RIP1/RIP3/MLKL-dependent necroptosis of myofibroblasts. These mechanistic insights have enabled the repurposing of LC as a therapeutic strategy to reverse established lung fibrosis in mouse models. Our findings provide a myofibroblast-targeting strategy and highlight its potential in PF treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lithium carbonate induces myofibroblast necroptosis to reverse pulmonary fibrosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月4日

查看全文
  • Keke Wei,
  • Liang Tang,
  • Xin Zhang,
  • Simin Liu,
  • Shuai Tong,
  • Yuhan Bian,
  • Yuan Ma,
  • Tao Zhu,
  • Jingxuan Xiao,
  • Qishun Lin,
  • Runze Zhang,
  • Jiadi Lv,
  • Huafeng Zhang,
  • Ke Tang,
  • Sha Wu,
  • Jingwei Ma,
  • Bo Huang

摘要

Pulmonary fibrosis (PF) is a fatal disease with limited therapeutic options. Myofibroblasts, central to the pathogenesis of PF, are the primary collagen-producing cells that drive fibrosis. However, therapeutic targeting of myofibroblasts faces formidable challenges owing to their autonomous activation, persistent proliferation, and resistance to apoptosis. Here, we show that lithium carbonate (LC), a clinically approved mood stabilizer, effectively depletes myofibroblasts during fibrosis progression. Mechanistically, LC promotes alveolar macrophages (AMs) to produce TNF-α, which activates pro-caspase-8 signaling without inducing myofibroblast apoptosis. LC directly binds to and inactivates pro-caspase-8, inducing to RIP1/RIP3/MLKL-dependent necroptosis of myofibroblasts. These mechanistic insights have enabled the repurposing of LC as a therapeutic strategy to reverse established lung fibrosis in mouse models. Our findings provide a myofibroblast-targeting strategy and highlight its potential in PF treatment.